Aspect Biosystems and big pharma giant from Novo Nordisk announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes. Since 2023, Aspect and Novo Nordisk have collaborated to develop cellular medicines designated to replace, repair, or supplement biological functions to deliver truly disease-modifying therapies. This new phase of the partnership builds on the momentum achieved in the existing collaboration.
